Mallinckrodt Pharmaceuticals, formerly Covidien, a specialist US biopharmaceutical company, aims to strengthen its hospital and autoimmune and rare diseases (ARD) businesses and focus on portfolio expansion.
To meet these aims, the company will create new general business manager roles across the organisation with four in key ARD therapeutic areas (rheumatology, neurology, nephrology, and pulmonology) and similar positions in its hospital and office brands franchises.
Mallinckrodt says internal candidates are being reviewed and external market searches are also underway.
With the company's focus on rapid expansion of the core business accelerated through partnership and acquisitions, Gary Phillips will resume his previous role as Mallinckrodt's Senior Vice President, Chief Strategy Officer, and lead strategy and business development and licensing efforts across the entire portfolio.
As the business builds its broader commercial organisation, Hugh O'Neill, Senior Vice President and President, Speciality Pharmaceuticals, will take responsibility for all speciality pharmaceutical commercial operations, including the hospital organisation which he currently oversees and, in the interim, the sales, support and service activities for the recently acquired ARD business, formerly Questcor Pharmaceuticals, acquired in August 2014. O'Neill will also continue to have responsibility for the company's broad market access activities.
